RU2016133285A3 - - Google Patents

Download PDF

Info

Publication number
RU2016133285A3
RU2016133285A3 RU2016133285A RU2016133285A RU2016133285A3 RU 2016133285 A3 RU2016133285 A3 RU 2016133285A3 RU 2016133285 A RU2016133285 A RU 2016133285A RU 2016133285 A RU2016133285 A RU 2016133285A RU 2016133285 A3 RU2016133285 A3 RU 2016133285A3
Authority
RU
Russia
Application number
RU2016133285A
Other languages
Russian (ru)
Other versions
RU2016133285A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016133285A publication Critical patent/RU2016133285A/ru
Publication of RU2016133285A3 publication Critical patent/RU2016133285A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016133285A 2014-01-15 2015-01-13 Фармацевтические комбинации RU2016133285A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305057 2014-01-15
EP14305057.3 2014-01-15
PCT/IB2015/050260 WO2015107461A1 (en) 2014-01-15 2015-01-13 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020121929A Division RU2020121929A (ru) 2014-01-15 2015-01-13 Фармацевтические комбинации

Publications (2)

Publication Number Publication Date
RU2016133285A RU2016133285A (ru) 2018-02-20
RU2016133285A3 true RU2016133285A3 (enExample) 2018-08-28

Family

ID=50033443

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020121929A RU2020121929A (ru) 2014-01-15 2015-01-13 Фармацевтические комбинации
RU2016133285A RU2016133285A (ru) 2014-01-15 2015-01-13 Фармацевтические комбинации

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2020121929A RU2020121929A (ru) 2014-01-15 2015-01-13 Фармацевтические комбинации

Country Status (11)

Country Link
US (2) US20160331755A1 (enExample)
EP (1) EP3094340A1 (enExample)
JP (2) JP2017502989A (enExample)
KR (1) KR20160101027A (enExample)
CN (2) CN112535688A (enExample)
AU (2) AU2015207723A1 (enExample)
BR (1) BR112016012141A2 (enExample)
CA (1) CA2936783A1 (enExample)
MX (1) MX2016009226A (enExample)
RU (2) RU2020121929A (enExample)
WO (1) WO2015107461A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757734A (zh) * 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
CN115040523A (zh) * 2021-03-09 2022-09-13 上海翰森生物医药科技有限公司 Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO2006077425A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3-激酶抑制剂及激素类药物的抗癌组合物
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2558463A1 (en) * 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Also Published As

Publication number Publication date
CN105916515A (zh) 2016-08-31
JP2020023497A (ja) 2020-02-13
EP3094340A1 (en) 2016-11-23
RU2016133285A (ru) 2018-02-20
CA2936783A1 (en) 2015-07-23
MX2016009226A (es) 2016-10-05
WO2015107461A1 (en) 2015-07-23
AU2017245302A1 (en) 2017-11-02
JP2017502989A (ja) 2017-01-26
US20160331755A1 (en) 2016-11-17
KR20160101027A (ko) 2016-08-24
CN112535688A (zh) 2021-03-23
US20170304311A1 (en) 2017-10-26
AU2017245302B2 (en) 2019-04-04
RU2020121929A (ru) 2020-07-13
AU2015207723A1 (en) 2016-06-09
BR112016012141A2 (pt) 2017-08-08
US10085996B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
BR112016016761A2 (enExample)
BR112016015519A2 (enExample)
BR112016015813A2 (enExample)
BR112016027570A2 (enExample)
BR112016016490A2 (enExample)
BR112016016546A2 (enExample)
BR112016014949A2 (enExample)
BR112016016612A2 (enExample)
BR112015027867A2 (enExample)
BR112016016421A2 (enExample)
BR112016016446A2 (enExample)
BR112016016106A2 (enExample)
BR112016016558A2 (enExample)
BR112016015938A2 (enExample)
BR112016015915A2 (enExample)
BR112016015542A2 (enExample)
BR112016016468A2 (enExample)
BR112016016389A2 (enExample)
BR112016016459A2 (enExample)
BR112016016537A2 (enExample)
BR112016003522A2 (enExample)
BR112016015133A2 (enExample)
BR112016015911A2 (enExample)
BR112016014482A2 (enExample)
BR112016016798A2 (enExample)